0       0

2017 Annual Meeting


044 - SESSION 44: Optimizing Early Outcomes after Lung Transplantation


Apr 8, 2017 8:00am ‐ Apr 8, 2017 9:30am

Description

(478) Relationship of Early Lung Allograft Injury as Measured by Cell Free DNA with Donor and Recipient Characteristics
Si Pham, MD

(479) Cell-Free DNA in Human Ex-Vivo Lung Perfusate as a Potential Biomarker to Predict the Risk of Primary Graft Dysfunction (PGD) in Lung Transplantation
Takashi Kanou, MD

(483) Early CMV Management Post Lung Transplant(LTx): A 6-Year Review of Pre-Emptive Strategy for CMV
Karthik Santhanakrishnan, MBBS, MRCP

(481) Gene Expression Profiling of Bronchoalveolar Lavage Cells During Lung Allograft Acute Rejection
Sam Weigt, MD

(482) Treatment of Antibody Mediated Rejection of the Lung Allograft with Carfilzomib-Based Therapy
Christopher Ensor, PharmD, BCPS-CV

(480) The Association of IL-6 and IL-8 within 72 Hours Post-Transplant and Short and Long Term Outcome
Stijn Verleden, PhD

Speaker(s):

Tags: ID LTX PHARM BSTR PATH

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content